AI firm Insitro signs Gilead as first pharma partner with NASH dealLess than a year after coming out of stealth mode with a $65 million first-round last year, artificial Share XAI firm Insitro signs Gilead as first pharma partner with NASH dealhttps://pharmaphorum.com/digital/ai-insitro-gilead-pharma-partner/
Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
ViiV hopes for blockbuster with HIV drug combo approvalThe FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for Share XViiV hopes for blockbuster with HIV drug combo approvalhttps://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/
Gilead files Truvada follow-up Descovy for PrEPGilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending Share XGilead files Truvada follow-up Descovy for PrEPhttps://pharmaphorum.com/news/gilead-files-truvada-follow-up-descovy-for-prep/
R&D round-up: Non-opioid painkiller space heats upAs the MHRA announced that it would be convening an Expert Working Group (EWG) to assess the risks Share XR&D round-up: Non-opioid painkiller space heats uphttps://pharmaphorum.com/views-and-analysis/rd-roundup-non-opioid-painkiller-space-heats-up/
Once-a-month HIV treatment sees promising phase III resultsJanssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III Share XOnce-a-month HIV treatment sees promising phase III resultshttps://pharmaphorum.com/news/once-a-month-hiv-treatment-sees-promising-phase-iii-results/
Gilead NASH drug fails late stage trialGilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a Share XGilead NASH drug fails late stage trialhttps://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/
Pharma companies clear the R&D decks in Q4The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as Share XPharma companies clear the R&D decks in Q4https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/
Gilead hires Roche’s pharma chief Daniel O’Day as CEORoche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO Share XGilead hires Roche’s pharma chief Daniel O’Day as CEOhttps://pharmaphorum.com/news/gilead-hires-roches-pharma-chief-daniel-oday-as-ceo/
